---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-056316"
form_type: "8-K"
ticker: "PAHC"
cik: "0001069899"
company_name: "PHIBRO ANIMAL HEALTH CORP"
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:27:32.889345+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phibro Animal Health Q3 FY2026: Sales $383.5M (+10%), Adj. EBITDA $60.8M (+11%); Guidance raised

## Summary
- Q3 net sales $383.5M, +10% YoY; Animal Health segment +13% to $291.2M, driven by MFA portfolio, nutritional specialties, vaccines.
- Net income $24.0M, +15%; diluted EPS $0.59; adjusted diluted EPS $0.76, +19% YoY.
- Updated FY2026 guidance: net sales $1.46B-$1.50B (14% growth), adjusted EBITDA $247M-$255M (37% growth).
- Post-quarter: expanded revolver by $125M to $435M; announced Sustainable Solutions Platform with VERRATAIN; Brazil regulatory development on antimicrobials noted.
- Gross margin improved 270 bps to 32.8%; free cash flow $12.8M trailing twelve months; leverage 3.1x.

## SEC filing metadata
- accession: 0001104659-26-056316
- form_type: 8-K
- ticker: PAHC
- cik: 0001069899
- company_name: PHIBRO ANIMAL HEALTH CORP
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069899/000110465926056316/0001104659-26-056316-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069899/000110465926056316/pahc-20260506x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-056316
- JSON: https://secwatch.observer/filing/0001104659-26-056316.json
- Plain text: https://secwatch.observer/filing/0001104659-26-056316.txt

## Source-grounded claims
- claim_id: 7dd2ce3b7b9bf5311cb1310a1abaf4279fe8b648
  claim: PHIBRO ANIMAL HEALTH CORP reported third quarter ended March 31, 2026 results: revenue $383.5 million, net income $24.0 million, EPS $0.59. Guidance reaffirmed.
  evidence_excerpt: guidance for the year ending June 30, 2026. ​ Highlights for the three months ended March 31, 2026 (compared to the three months ended March 31, 2025): ​ - Net sales of $383.5 million, an increase of $35.7 million, or 10% - Net income of $24.0 million, an increase of $3.1 million, or 15% - Diluted earnings per share of $0.59, an increase of $0.08, or 16% -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069899/000110465926056316/0001104659-26-056316-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.